Patents by Inventor Andreas Petri

Andreas Petri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTISENSE OLIGOMERS TARGETING PCSK9
    Publication number: 20240084307
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Application
    Filed: June 30, 2023
    Publication date: March 14, 2024
    Inventors: Nanna ALBÆK, Maj HEDTJÄRN, Marie Wickstrom LINDHOLM, Niels Fisker NIELSEN, Andreas PETRI, Jacob RAVN
  • ANTISENSE OLIGONUCLEOTIDES FOR MODULATION OF LONG NONCODING RNAS
    Publication number: 20230348911
    Abstract: The present invention relates to noncoding RNAs as novel disease targets, and methods of modulating the activity of such ncRNA targets in patients. In particular, the invention relates to modulation of long non-coding RNAs, such as circular RNAs (circRNAs) or large intergenic noncoding RNAs (lincRNAs) in cancer using antisense oligonucleotides.
    Type: Application
    Filed: June 8, 2017
    Publication date: November 2, 2023
    Inventors: Sakari Kauppinen, Andreas Petri, Charlotte Albæk Thrue
  • Antisense oligomers targeting PCSK9
    Patent number: 11739332
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: August 29, 2023
    Assignee: ROCHE INNOVATION CENTER COPENHAGEN A/S
    Inventors: Nanna Albæk, Maj Hedtjärn, Marie Wickstrom Lindholm, Niels Fisker Nielsen, Andreas Petri, Jacob Ravn
  • INHIBITORS OF MICRO-RNA 22
    Publication number: 20230181613
    Abstract: The present disclosure provides compositions and methods that inhibit the activity of microRNAs, for example miR-22.
    Type: Application
    Filed: October 12, 2022
    Publication date: June 15, 2023
    Inventors: Pier Paolo PANDOLFI, Riccardo PANELLA, Sakari KAUPPINEN, Andreas PETRI
  • Inhibitors of micro-RNA 22
    Patent number: 11499152
    Abstract: The present disclosure provides compositions and methods that inhibit the activity of microRNAs, for example miR-22.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: November 15, 2022
    Assignees: Beth Israel Deaconess Medical Center, Aalborg University
    Inventors: Pier Paolo Pandolfi, Riccardo Panella, Sakari Kauppinen, Andreas Petri
  • ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
    Publication number: 20220354888
    Abstract: The present invention provides antisense oligonucleotides directed against immune checkpoints and methods and compositions of using such antisense oligonucleotides for the treatment of cancer.
    Type: Application
    Filed: August 3, 2017
    Publication date: November 10, 2022
    Inventors: Sakari Kauppinen, Andreas Petri, Charlotte Albæk Thrue
  • Therapeutic Targeting of a microRNA to Treat Duchenne Muscular Dystrophy
    Publication number: 20220213477
    Abstract: Methods of treating Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), comprising administering an inhibitory nucleic acid that targets miR-128.
    Type: Application
    Filed: December 21, 2021
    Publication date: July 7, 2022
    Inventors: Anders M. Naar, Sakari Kauppinen, Andreas Petri
  • Therapeutic targeting of a microRNA to treat Duchenne muscular dystrophy
    Patent number: 11236336
    Abstract: Methods of treating Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), comprising administering an inhibitory nucleic acid that targets miR-128.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: February 1, 2022
    Assignees: The General Hospital Corporation, Aalborg University
    Inventors: Anders M. Naar, Sakari Kauppinen, Andreas Petri
  • ANTISENSE OLIGOMERS TARGETING PCSK9
    Publication number: 20220025376
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Application
    Filed: July 16, 2021
    Publication date: January 27, 2022
    Inventors: Nanna ALBÆK, Maj HEDTJÄRN, Marie Wickstrom LINDHOLM, Niels Fisker NIELSEN, Andreas PETRI, Jacob RAVN
  • Antisense oligomers targeting PCSK9
    Patent number: 11091764
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: August 17, 2021
    Assignee: ROCHE INNOVATION CENTER COPENHAGEN A/S
    Inventors: Nanna Albæk, Maj Hedtjärn, Marie Wickstrom Lindholm, Niels Fisker Nielsen, Andreas Petri, Jacob Ravn
  • INHIBITORS OF MICRO-RNA 22
    Publication number: 20210017521
    Abstract: The present disclosure provides compositions and methods that inhibit the activity of microRNAs, for example miR-22.
    Type: Application
    Filed: March 14, 2019
    Publication date: January 21, 2021
    Inventors: Pier Paolo PANDOLFI, Riccardo PANELLA, Sakari KAUPPINEN, Andreas PETRI
  • Therapeutic Targeting of a microRNA to Treat Duchenne Muscular Dystrophy
    Publication number: 20200362342
    Abstract: Methods of treating Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), comprising administering an inhibitory nucleic acid that targets miR-128.
    Type: Application
    Filed: March 24, 2020
    Publication date: November 19, 2020
    Inventors: Anders M. Naar, Sakari Kauppinen, Andreas Petri
  • Antisense oligomers targeting HOXB-AS3 long non-coding RNA
    Patent number: 10787665
    Abstract: The present disclosure relates to antisense oligomers targeting the long non-coding RNA HOXB-AS3 and methods of treating acute myeloid leukemia.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: September 29, 2020
    Assignees: Ohio State Innovation Foundation, Aalborg University
    Inventors: Ramiro Garzon, Adrienne Dorrance, Dimitrios Papaioannou, Robert Lee, Sakari Kauppinen, Andreas Petri, Charlotte AlbÆk Thrue
  • ANTISENSE OLIGOMERS TARGETING PCSK9
    Publication number: 20200248186
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Application
    Filed: September 4, 2019
    Publication date: August 6, 2020
    Inventors: Nanna ALBÆK, Maj HEDTJÄRN, Marie Wickstrom LINDHOLM, Niels Fisker NIELSEN, Andreas PETRI, Jacob RAVN
  • Ketoreductases
    Patent number: 10724008
    Abstract: The invention relates to ketoreductases and the use thereof. The ketoreductases of the invention are particularly useful for enzymatically catalyzing the reduction of ketones to chiral secondary alcohols.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: July 28, 2020
    Assignee: C-LEcta GmbH
    Inventors: Ramona Schmiedel, Andreas Vogel, Sabrina Koepke, Rico Czaja, Claudia Feller, Hedda Merkens, Kamila Rzeznicka, Daniel Schwarze, Thomas Greiner-Stoeffele, Andreas Petri, Marc Struhalla
  • Therapeutic targeting of a microRNA to treat Duchenne muscular dystrophy
    Patent number: 10626395
    Abstract: Methods of treating Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), comprising administering an inhibitory nucleic acid that targets miR-128.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: April 21, 2020
    Assignees: The General Hospital Corporation, Aalborg University
    Inventors: Anders M. Naar, Sakari Kauppinen, Andreas Petri
  • TARGETING HUMAN SATELLITE II (HSATII)
    Publication number: 20200017856
    Abstract: Methods for treating cancer, e.g., cancer of epithelial origin, by specifically targeting human satellite II (HSATII) using sequence specific agents such as oligonucleotides.
    Type: Application
    Filed: April 24, 2019
    Publication date: January 16, 2020
    Inventors: David T. Ting, Daniel A. Haber, Shyamala Maheswaran, Francesca Bersani, Anders M. Naar, Mihir Shivadatta Rajurkar, Sakari Kauppinen, Andreas Petri
  • Antisense oligomers targeting PCSK9
    Patent number: 10443058
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: October 15, 2019
    Assignee: ROCHE INNOVATION CENTER COPENHAGEN A/S
    Inventors: Nanna Albæk, Maj Hedtjärn, Marie Wickstrom Lindholm, Niels Fisker Nielsen, Andreas Petri, Jacob Ravn
  • Therapeutic Targeting of a microRNA to Treat Duchenne Muscular Dystrophy
    Publication number: 20190270993
    Abstract: Methods of treating Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), comprising administering an inhibitory nucleic acid that targets miR-128.
    Type: Application
    Filed: September 18, 2017
    Publication date: September 5, 2019
    Inventors: Anders M. Naar, Sakari Kauppinen, Andreas Petri
  • ANTISENSE OLIGOMERS TARGETING HOXB-AS3 LONG NON-CODING RNA
    Publication number: 20190256848
    Abstract: The present disclosure relates to antisense oligomers targeting the long non-coding RNA HOXB-AS3 and methods of treating acute myeloid leukemia.
    Type: Application
    Filed: November 3, 2017
    Publication date: August 22, 2019
    Inventors: Ramiro GARZON, Adrienne DORRANCE, Dimitrios PAPAIOANNOU, Robert LEE, Sakari KAUPPINEN, Andreas PETRI, Charlotte ALBÆK THRUE